These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

108 related articles for article (PubMed ID: 23604228)

  • 1. Anti-oxidant vitamin E prevents accumulation of imatinib-resistant BCR-ABL1 kinase mutations in CML-CP xenografts in NSG mice.
    Nieborowska-Skorska M; Hoser G; Hochhaus A; Stoklosa T; Skorski T
    Leukemia; 2013 Nov; 27(11):2253-4. PubMed ID: 23604228
    [No Abstract]   [Full Text] [Related]  

  • 2. Persistence of leukemia stem cells in chronic myelogenous leukemia patients in prolonged remission with imatinib treatment.
    Chu S; McDonald T; Lin A; Chakraborty S; Huang Q; Snyder DS; Bhatia R
    Blood; 2011 Nov; 118(20):5565-72. PubMed ID: 21931114
    [TBL] [Abstract][Full Text] [Related]  

  • 3. E255K and G250E mutation appearing in a patient with e19a2 chronic myeloid leukemia resistant to imatinib.
    Li C; Wang Y; Xu D; Zhang P; Ding X; Zhang N; Xiao M; Huang L; Meng L
    Clin Lab; 2015; 61(1-2):183-6. PubMed ID: 25807654
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dipeptidylpeptidase IV (CD26) defines leukemic stem cells (LSC) in chronic myeloid leukemia.
    Herrmann H; Sadovnik I; Cerny-Reiterer S; Rülicke T; Stefanzl G; Willmann M; Hoermann G; Bilban M; Blatt K; Herndlhofer S; Mayerhofer M; Streubel B; Sperr WR; Holyoake TL; Mannhalter C; Valent P
    Blood; 2014 Jun; 123(25):3951-62. PubMed ID: 24778155
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Molecular and functional analysis of the stem cell compartment of chronic myelogenous leukemia reveals the presence of a CD34- cell population with intrinsic resistance to imatinib.
    Lemoli RM; Salvestrini V; Bianchi E; Bertolini F; Fogli M; Amabile M; Tafuri A; Salati S; Zini R; Testoni N; Rabascio C; Rossi L; Martin-Padura I; Castagnetti F; Marighetti P; Martinelli G; Baccarani M; Ferrari S; Manfredini R
    Blood; 2009 Dec; 114(25):5191-200. PubMed ID: 19855080
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [The efficacy analysis of interferon combined with imatinib in chronic myelogenous leukemia patients with ABL kinase domain mutations].
    Zu YL; Zhang YL; Zhou J; Zhao HF; Gui RR; Li Z; Gao SK; Song YP
    Zhonghua Nei Ke Za Zhi; 2016 Oct; 55(10):794-796. PubMed ID: 27686442
    [TBL] [Abstract][Full Text] [Related]  

  • 7. PD166326, a novel tyrosine kinase inhibitor, has greater antileukemic activity than imatinib mesylate in a murine model of chronic myeloid leukemia.
    Wolff NC; Veach DR; Tong WP; Bornmann WG; Clarkson B; Ilaria RL
    Blood; 2005 May; 105(10):3995-4003. PubMed ID: 15657179
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Aberrant signalling by protein kinase CK2 in imatinib-resistant chronic myeloid leukaemia cells: biochemical evidence and therapeutic perspectives.
    Borgo C; Cesaro L; Salizzato V; Ruzzene M; Massimino ML; Pinna LA; Donella-Deana A
    Mol Oncol; 2013 Dec; 7(6):1103-15. PubMed ID: 24012109
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dasatinib induces notable hematologic and cytogenetic responses in chronic-phase chronic myeloid leukemia after failure of imatinib therapy.
    Hochhaus A; Kantarjian HM; Baccarani M; Lipton JH; Apperley JF; Druker BJ; Facon T; Goldberg SL; Cervantes F; Niederwieser D; Silver RT; Stone RM; Hughes TP; Muller MC; Ezzeddine R; Countouriotis AM; Shah NP
    Blood; 2007 Mar; 109(6):2303-9. PubMed ID: 17138817
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dihydroartemisinin inhibits the Bcr/Abl oncogene at the mRNA level in chronic myeloid leukemia sensitive or resistant to imatinib.
    Lee J; Shen P; Zhang G; Wu X; Zhang X
    Biomed Pharmacother; 2013 Mar; 67(2):157-63. PubMed ID: 23201011
    [TBL] [Abstract][Full Text] [Related]  

  • 11. ApoptomiRs expression modulated by BCR-ABL is linked to CML progression and imatinib resistance.
    Ferreira AF; Moura LG; Tojal I; Ambrósio L; Pinto-Simões B; Hamerschlak N; Calin GA; Ivan C; Covas DT; Kashima S; Castro FA
    Blood Cells Mol Dis; 2014; 53(1-2):47-55. PubMed ID: 24629639
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Marked ploidy and BCR-ABL gene amplification in vivo in a patient treated with STI571.
    Sirulink A; Silver RT; Najfeld V
    Leukemia; 2001 Nov; 15(11):1795-7. PubMed ID: 11681425
    [No Abstract]   [Full Text] [Related]  

  • 13. Disappearance of both the BCR/ABL1 fusion gene and the JAK2V617F mutation with dasatinib therapy in a patient with imatinib-resistant chronic myelogenous leukemia.
    Inokuchi K; Yamaguchi H; Tamai H; Dan K
    J Clin Exp Hematop; 2012; 52(2):145-7. PubMed ID: 23037633
    [No Abstract]   [Full Text] [Related]  

  • 14. Detection of BCR-ABL kinase mutations in CD34+ cells from chronic myelogenous leukemia patients in complete cytogenetic remission on imatinib mesylate treatment.
    Chu S; Xu H; Shah NP; Snyder DS; Forman SJ; Sawyers CL; Bhatia R
    Blood; 2005 Mar; 105(5):2093-8. PubMed ID: 15345592
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Association between imatinib-resistant BCR-ABL mutation-negative leukemia and persistent activation of LYN kinase.
    Wu J; Meng F; Kong LY; Peng Z; Ying Y; Bornmann WG; Darnay BG; Lamothe B; Sun H; Talpaz M; Donato NJ
    J Natl Cancer Inst; 2008 Jul; 100(13):926-39. PubMed ID: 18577747
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Frequency of BCR-ABL gene mutations in Polish patients with chronic myeloid leukemia treated with imatinib: a final report of the MAPTEST study.
    Lewandowski K; Warzocha K; Hellmann A; Skotnicki A; Prejzner W; Foryciarz K; Sacha T; Gniot M; Majewski M; Solarska I; Nowak G; Wasag B; Kobelski M; Scibiorski C; Siemiatkowski M; Lewandowska M; Komarnicki M
    Pol Arch Med Wewn; 2009 Dec; 119(12):789-94. PubMed ID: 20010464
    [TBL] [Abstract][Full Text] [Related]  

  • 17. STI571 as a targeted therapy for CML.
    O'Dwyer ME; Mauro MJ; Druker BJ
    Cancer Invest; 2003 Jun; 21(3):429-38. PubMed ID: 12901289
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Polo-like kinase 1 (Plk1) as a novel drug target in chronic myeloid leukemia: overriding imatinib resistance with the Plk1 inhibitor BI 2536.
    Gleixner KV; Ferenc V; Peter B; Gruze A; Meyer RA; Hadzijusufovic E; Cerny-Reiterer S; Mayerhofer M; Pickl WF; Sillaber C; Valent P
    Cancer Res; 2010 Feb; 70(4):1513-23. PubMed ID: 20145140
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effective killing of Gleevec-resistant CML cells with T315I mutation by a natural compound PEITC through redox-mediated mechanism.
    Zhang H; Trachootham D; Lu W; Carew J; Giles FJ; Keating MJ; Arlinghaus RB; Huang P
    Leukemia; 2008 Jun; 22(6):1191-9. PubMed ID: 18385754
    [TBL] [Abstract][Full Text] [Related]  

  • 20. INNO-406, a novel BCR-ABL/Lyn dual tyrosine kinase inhibitor, suppresses the growth of Ph+ leukemia cells in the central nervous system, and cyclosporine A augments its in vivo activity.
    Yokota A; Kimura S; Masuda S; Ashihara E; Kuroda J; Sato K; Kamitsuji Y; Kawata E; Deguchi Y; Urasaki Y; Terui Y; Ruthardt M; Ueda T; Hatake K; Inui K; Maekawa T
    Blood; 2007 Jan; 109(1):306-14. PubMed ID: 16954504
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.